Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 65Carcinoma, Non-Small-Cell Lung 39Breast Neoplasms 32Triple Negative Breast Neoplasms 25Neoplasm Metastasis 18Neoplasms 15Lung Neoplasms 15Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 6Ovarian Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Head and Neck Neoplasms 5Gallbladder Neoplasms 5Fallopian Tube Neoplasms 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Pancreatic Ductal 4Carcinoma 4Adenocarcinoma 4Neoplasms by Site 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Vaccinia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

atezolizumab 2pembrolizumab 1liposomal doxorubicin 1Tumor Necrosis Factor-alpha 1Gemcitabine 1Cell Count 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoviridae Infections × 130-nm albumin-bound paclitaxel × 1 year × Clear all
NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Lokon Pharma AB

Phase 1/2 Completed
51 enrolled
Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡